Literature DB >> 21693159

Spontaneously Hypertensive Rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine.

Raquel Levin1, Mariana Bendlin Calzavara, Camila Maurício Santos, Wladimir Agostini Medrano, Suzy Tamie Niigaki, Vanessa Costhek Abílio.   

Abstract

Deficits in an operational measure of sensorimotor gating - the prepulse inhibition of startle (PPI) - are presented in psychiatric disorders such as schizophrenia, bipolar disorder, and attention deficit/hyperactivity disorder (ADHD). Some previous studies showed that the spontaneously hypertensive rats (SHR) present PPI deficit. Although SHR is suggested as an animal model to study ADHD, we have suggested that the behavioral phenotype of this strain mimics some aspects of schizophrenia. The aim of this study was to characterize the PPI response in SHR. Pharmacological characterization consisted in the evaluation of the effects of the following drugs administered to adult Wistar rats (WR) and SHR previously to the PPI test: amphetamine (used for ADHD and also a psychotomimetic drug), haloperidol and clozapine (antipsychotic drugs), metoclopramide (dopamine antagonist without antipsychotic properties) and carbamazepine (mood stabilizer). Our results showed that SHR presented reduced PPI. This deficit was similar to that induced by amphetamine in WR. Only the atypical antipsychotic clozapine improved the PPI deficit observed in SHR. These findings reinforce the SHR strain as an animal model to study several aspects of schizophrenia, including the abnormalities in sensorimotor gating associated with this disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21693159     DOI: 10.1016/j.pnpbp.2011.06.003

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  13 in total

1.  Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats.

Authors:  Thiago Garcia Varga; Juan Guilherme de Toledo Simões; Amanda Siena; Elisandra Henrique; Regina Cláudia Barbosa da Silva; Vinicius Dos Santos Bioni; Aline Camargo Ramos; Tatiana Rosado Rosenstock
Journal:  Psychopharmacology (Berl)       Date:  2021-06-05       Impact factor: 4.530

2.  Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain.

Authors:  Mariana C Diana; Fernanda F Peres; Veronica Justi; Rodrigo A Bressan; Acioly L T Lacerda; José Alexandre Crippa; Jaime E C Hallak; Vanesssa Costhek Abilio
Journal:  CNS Neurosci Ther       Date:  2018-04-14       Impact factor: 5.243

Review 3.  Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.

Authors:  Marc A Mergy; Raajaram Gowrishankar; Gwynne L Davis; Tammy N Jessen; Jane Wright; Gregg D Stanwood; Maureen K Hahn; Randy D Blakely
Journal:  Neurochem Int       Date:  2013-12-08       Impact factor: 3.921

4.  Neonatal Immune Challenge with Lipopolysaccharide Triggers Long-lasting Sex- and Age-related Behavioral and Immune/Neurotrophic Alterations in Mice: Relevance to Autism Spectrum Disorders.

Authors:  Charllyany Sabino Custódio; Bruna Stefânia Ferreira Mello; Adriano José Maia Chaves Filho; Camila Nayane de Carvalho Lima; Rafaela Carneiro Cordeiro; Fábio Miyajima; Gislaine Z Réus; Silvânia Maria Mendes Vasconcelos; Tatiana Barichello; João Quevedo; Antônio Carlos de Oliveira; David Freitas de Lucena; Danielle S Macedo
Journal:  Mol Neurobiol       Date:  2017-05-23       Impact factor: 5.590

5.  Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.

Authors:  J F C Pedrazzi; A C Issy; F V Gomes; F S Guimarães; E A Del-Bel
Journal:  Psychopharmacology (Berl)       Date:  2015-05-06       Impact factor: 4.530

6.  Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain.

Authors:  Raquel Levin; Fernanda F Peres; Valéria Almeida; Mariana B Calzavara; Antonio W Zuardi; Jaime E C Hallak; José Alexandre S Crippa; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2014-02-06       Impact factor: 5.810

Review 7.  Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence.

Authors:  Cathrin Rohleder; Juliane K Müller; Bettina Lange; F M Leweke
Journal:  Front Pharmacol       Date:  2016-11-08       Impact factor: 5.810

Review 8.  Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy.

Authors:  Fernanda F Peres; Raquel Levin; Valéria Almeida; Antonio W Zuardi; Jaime E Hallak; José A Crippa; Vanessa C Abilio
Journal:  Front Pharmacol       Date:  2016-09-09       Impact factor: 5.810

9.  Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia.

Authors:  Fernanda F Peres; Mariana C Diana; Raquel Levin; Mayra A Suiama; Valéria Almeida; Ana M Vendramini; Camila M Santos; Antônio W Zuardi; Jaime E C Hallak; José A Crippa; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2018-08-21       Impact factor: 5.810

10.  Mitochondrial Dysfunction and Changes in High-Energy Compounds in Different Cellular Models Associated to Hypoxia: Implication to Schizophrenia.

Authors:  Luiz Felipe Souza E Silva; Mariana Dutra Brito; Jéssica Mayumi Camargo Yuzawa; Tatiana Rosado Rosenstock
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.